title: Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method.
abstract: We studied the effects of a non-narcotic, centrally acting antitussive, fominoben (PB89), on hypoxia in sixty patients suffering from chronic obstructive lung diseases (COLD), utilizing a double-blind method and using the antitussive dextromethorphan as a reference drug. By the oral administration of a dose of 2 fominoben tablets (160 mg) three times a day for 2 weeks, a significant increase in arterial O2 pressure (PaO2), a decrease in arterial CO2 pressure (PaCO2), and a rise in pH were observed. However, alveolar-arterial O2 difference (A-aDO2) was not improved. On the other hand, after administration of a dose of 2 dextromethorphan tablets (30 mg) three times a day for 2 weeks, no increase in PaO2, no decrease in PaCo2 and no improvement in A-aDO2 were observed, although a rise in pH was seen. The increase in PaO2 by fominoben was marked in COLD with dyspnoea. No improvement of A-aDO2 despite a decrease in PaCO2 suggests that fominoben might increase alveolar ventilation, in spite of its effect as an antitussive, exerting a favourable effect on hypoxia. It is, therefore, speculated that the cough centre and the respiratory centre are capable of functioning independently of each other.
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Sugiyama
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Takishima
mesh_terms: D000368:Aged; D000996:Antitussive Agents; D003915:Dextromethorphan / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy* / Q000209:etiology; D007981:Levorphanol / Q000031:analogs & derivatives*; D008173:Lung Diseases, Obstructive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010313:Partial Pressure; D012125:Respiratory Center / Q000187:drug effects
chemical_list: D000996:Antitussive Agents; D009025:Morpholines; D007981:Levorphanol; D003915:Dextromethorphan